Eagle Pharmaceuticals (EGRX) : Investors lapped up stocks on upticks to the tune of $7.49 million in the Wednesdays trading session. The trading value on downticks was comparatively at $5.28 million and the uptick to downtick ratio of 1.42 indicates continuous buying by the bulls. The net money flow into the stock was $2.21 million. Upticks saw transactions worth $2.91 clearly indicating buying by large investors. The total money flow for block trades stood at $2.91 million, which is a positive for the stock in the long-term. Eagle Pharmaceuticals (EGRX) fell $0.27 during the day at $69.45, a drop of -0.39% over the previous days close. However, for the week, the stock is 4.78%, compared to the previous week.
Shares of Eagle Pharmaceuticals Inc. rose by 6.27% in the last five trading days and 16.56% for the last 4 weeks. Eagle Pharmaceuticals Inc. is up 80.68% in the last 3-month period. Year-to-Date the stock performance stands at -20.69%.
Eagle Pharmaceuticals (EGRX) : Zacks Investment Research ranks Eagle Pharmaceuticals (EGRX) as 3, which is a Hold recommendation. 2 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 4 research analysts is 1.75, which indicates as a Buy.
Eagle Pharmaceuticals (NASDAQ:EGRX): The stock opened at $70.18 and touched an intraday high of $71.37 on Wednesday. During the day, the stock corrected to an intraday low of $68.51, however, the bulls stepped in and pushed the price higher to close in the green at $70.32 with a gain of 0.86% for the day. The total traded volume for the day was 443,179. The stock had closed at $69.72 in the previous trading session.
Eagle Pharmaceuticals, Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD), an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda, and Ryanodex (dantrolene for MH), and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101, EP-3102, Ryanodex, EP-4104, EP-6101, EP-5101, EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.